Pioglitazone reduces monocyte activation in type 2 diabetes.

Pioglitazone reduces monocyte activation in type 2 diabetes.

Item
http://www.wikidata.org/entity/Q46344044
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusAdjunctive therapies and immunomodulating agents for severe influenza.Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.How to approach and treat viral infections in ICU patientsPioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.Immunomodulatory therapy for severe influenza.Reconfiguration of NKT Cell Subset Compartment Is Associated with Plaque Development in Patients with Carotid Artery Stenosis.9- and 13-HODE regulate fatty acid binding protein-4 in human macrophages, but does not involve HODE/GPR132 axis in PPAR-γ regulation of FABP4.
P2860

Pioglitazone reduces monocyte activation in type 2 diabetes.

Item
http://www.wikidata.org/entity/Q46344044
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pioglitazone reduces monocyte activation in type 2 diabetes.
@en
Pioglitazone reduces monocyte activation in type 2 diabetes.
@nl
type
label
Pioglitazone reduces monocyte activation in type 2 diabetes.
@en
Pioglitazone reduces monocyte activation in type 2 diabetes.
@nl
prefLabel
Pioglitazone reduces monocyte activation in type 2 diabetes.
@en
Pioglitazone reduces monocyte activation in type 2 diabetes.
@nl
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Pioglitazone reduces monocyte activation in type 2 diabetes
@en
P2093
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P921